Výsledky vyhledávání

Akademický článek

349 Early safety and efficacy of a phase 1/2 open-label, multi-center trial of SNS-301 added to pembrolizumab in patients with advanced squamous cell carcinoma of the head and neck (SCCHN)

Autor: William Smith, Jean Campbell, Timothy Panella, Dong Shin, Marie-Louise Fjaellskog, John Celebi, Alice Drumheller, Robert Pierce, Michael Guarino

Publikováno v: Journal for ImmunoTherapy of Cancer, Vol 8, Iss Suppl 3 (2020)

Externí odkaz: https://doaj.org/article/135041b375be40fc9d229c74261531e3

Zobrazit plný text záznamu

349 Early safety and efficacy of a phase 1/2 open-label, multi-center trial of SNS-301 added to pembrolizumab in patients with advanced squamous cell carcinoma of the head and neck (SCCHN)

Autor: John Celebi, Dong M. Shin, Alice Drumheller, Jean S. Campbell, Robert H. Pierce, William L. Smith, Alain Algazi, Marie-Louise Fjaellskog, Timothy Panella, Michael J. Guarino

Publikováno v: Journal for ImmunoTherapy of Cancer, Vol 8, Iss Suppl 3 (2020)

Background Efficacy of anti-PD-1 therapy is attributed to the presence of infiltrating antigen-specific CD8+ T-cells. Despite the success of anti-PD-1 therapy, many patients with SCCHN present with immune desert or immune excluded tumors and only 13�

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b186579f84ac8951f4499b27fb73717b
https://doi.org/10.1136/jitc-2020-sitc2020.0349

Zobrazit plný text záznamu

Update on safety and efficacy of a phase 1/2 of SNS-301 added to pembrolizumab in patients with advanced squamous cell carcinoma of the head and neck (SCCHN)

Autor: Lauren Abell, Robert H. Pierce, Jean S. Campbell, Timothy Panella, Dhaval Shah, Ramzi Melhem, Dong M. Shin, William Cairns Stewart Smith, John Celebi, Marie-Louise Fjaellskog, Ann Wild Gramza, Justine Yang Bruce, Alain Algazi

Publikováno v: Journal of Clinical Oncology. 39:6029-6029

6029 Background: The absence of infiltrating antigen-specific CD8+ T-cells at baseline is associated with low response rates to PD-1 blockade. SCCHN tumors often exclude effector T cells, and 2nd line response rates are low (13-18%). Highly immunogen

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::71d3ef4babc3c263c970f0b047d69f16
https://doi.org/10.1200/jco.2021.39.15_suppl.6029

Zobrazit plný text záznamu

924P SNS-301 added to pembrolizumab in patients (Pts) with ASPH+ advanced squamous cell carcinoma of the head & neck (SCCHN)

Autor: Alain Algazi, Robert H. Pierce, Jean S. Campbell, Timothy Panella, A. Drumheller, John Celebi, Michael J. Guarino, I. Csiki, W.B. Smith

Publikováno v: Annals of Oncology. 31:S666

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::bc6e84d26ff04997114a0ab74088bdb5
https://doi.org/10.1016/j.annonc.2020.08.1039

Zobrazit plný text záznamu

Safety/efficacy of a phase I/II study of SNS-301 added to pembrolizumab in patients with ASPH+ locally advanced unresectable or metastatic/recurrent squamous cell carcinoma of the head and neck (SCCHN)

Autor: Alice Drumheller, Robert H. Pierce, William L. Smith, Ildiko Csiki, John Celebi, Alain Algazi

Publikováno v: Journal of Clinical Oncology. 38:e18510-e18510

e18510 Background: SNS-301 is a first-in-class immune activating agent targeting human aspartyl (asparaginyl) β-hydroxylase (ASPH). ASPH is overexpressed in +20 tumor types. SNS-301 is an inactivated λ-bacteriophage, engineered to express a highly

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::1acf7299dcf5a5f6b933c0c0cae9be52
https://doi.org/10.1200/jco.2020.38.15_suppl.e18510

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání